Article

Study to evaluate dual AMD therapy

Cleveland-The Cleveland Clinic's Cole Eye Institute will lead a large, multicenter clinical trial to explore combination therapy for wet age-related macular degeneration (AMD).

Cleveland-The Cleveland Clinic's Cole Eye Institute will lead a large, multicenter clinical trial to explore combination therapy for wet age-related macular degeneration (AMD).

The 2-year, randomized, double-masked, controlled multi-center phase IIIb study will assess the safety and efficacy of verteporfin (Visudyne, Novartis Ophthalmics) administered in conjunction with intravitreal ranibizumab (Lucentis, Genentech) in patients with subfoveal choroidal neovascularization (CNV) secondary to wet AMD. The study, which is being called DENALI, will take place at 45 centers in the United States and five in Canada.

"We are exploring the potential to improve outcomes and reduce the frequency of treatments by combining therapies that target different mechanisms responsible for the development of AMD," said Peter Kaiser, MD, the study's lead investigator and an ophthalmologist at Cole Eye Institute.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.